ESR1 and breast carcinoma: BRCA testing should be proposed to any patient with ER+ advanced breast cancer and resistance to endocrine therapy [33,34,35] because PARPi therapy represents a treatment option in gBRCA patients and has a higher benefit/risk ratio than chemotherapy, as recently recognized by ESMO [36,37].